188 related articles for article (PubMed ID: 37697224)
1. Ceftazidime-avibactam alone or in combination with Aztreonam versus Polymyxins in the management of carbapenem-Resistant Klebsiella pneumoniae nosocomial Infections (CAPRI study): a retrospective cohort study from South India.
Sree RA; Gupta A; Gupta N; Veturi S; Reddy LSK; Begum M; Shravani E; Challa HR; Reddy SS; Singamsetty A; Arumilli M; Reddy PN; Tirlangi PK
Infection; 2024 Apr; 52(2):429-437. PubMed ID: 37697224
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the synergistic effect of eravacycline and tigecycline against carbapenemase-producing carbapenem-resistant Klebsiella pneumoniae.
Huang YS; Yang JL; Wang JT; Sheng WH; Yang CJ; Chuang YC; Chang SC
J Infect Public Health; 2024 May; 17(5):929-937. PubMed ID: 38599013
[TBL] [Abstract][Full Text] [Related]
4. Monitoring Ceftazidime-Avibactam and Aztreonam Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp. Carrying Both Klebsiella pneumoniae Carbapenemase-4 and New Delhi Metallo-β-Lactamase-1.
Yasmin M; Fouts DE; Jacobs MR; Haydar H; Marshall SH; White R; D'Souza R; Lodise TP; Rhoads DD; Hujer AM; Rojas LJ; Hoyen C; Perez F; Edwards A; Bonomo RA
Clin Infect Dis; 2020 Aug; 71(4):1095-1098. PubMed ID: 31802119
[TBL] [Abstract][Full Text] [Related]
5. Mechanistic Insights to Combating NDM- and CTX-M-Coproducing Klebsiella pneumoniae by Targeting Cell Wall Synthesis and Outer Membrane Integrity.
Smith NM; Boissonneault KR; Chen L; Petraitis V; Petraitiene R; Tao X; Zhou J; Lang Y; Kavaliauskas P; Bulman ZP; Holden PN; Cha R; Bulitta JB; Kreiswirth BN; Walsh TJ; Tsuji BT
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0052722. PubMed ID: 35924913
[TBL] [Abstract][Full Text] [Related]
6. Successful Treatment of
Perrotta F; Perrini MP
Medicina (Kaunas); 2021 Apr; 57(5):. PubMed ID: 33924769
[TBL] [Abstract][Full Text] [Related]
7.
Monogue ML; Abbo LM; Rosa R; Camargo JF; Martinez O; Bonomo RA; Nicolau DP
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416558
[TBL] [Abstract][Full Text] [Related]
8. Development of Resistance to Eravacycline by Klebsiella pneumoniae and Collateral Sensitivity-Guided Design of Combination Therapies.
Xu C; Wei X; Jin Y; Bai F; Cheng Z; Chen S; Pan X; Wu W
Microbiol Spectr; 2022 Oct; 10(5):e0139022. PubMed ID: 35972286
[TBL] [Abstract][Full Text] [Related]
9. Aztreonam plus ceftazidime-avibactam as treatment of NDM-1-producing Klebsiella pneumoniae bacteraemia in a neutropenic patient: Last resort therapy?
Bocanegra-Ibarias P; Camacho-Ortiz A; Garza-González E; Flores-Treviño S; Kim H; Perez-Alba E
J Glob Antimicrob Resist; 2020 Dec; 23():417-419. PubMed ID: 33212285
[TBL] [Abstract][Full Text] [Related]
10. Will ceftazidime/avibactam plus aztreonam be effective for NDM and OXA-48-Like producing organisms: Lessons learnt from
Pragasam AK; Veeraraghavan B; Shankar BA; Bakthavatchalam YD; Mathuram A; George B; Chacko B; Korula P; Anandan S
Indian J Med Microbiol; 2019; 37(1):34-41. PubMed ID: 31424008
[TBL] [Abstract][Full Text] [Related]
11. Ceftazidime-avibactam and aztreonam combination for Carbapenem-resistant Enterobacterales bloodstream infections with presumed
Gupta N; Boodman C; Prayag P; Manesh A; Kumar TP
Expert Rev Anti Infect Ther; 2024 Apr; 22(4):203-209. PubMed ID: 38258529
[TBL] [Abstract][Full Text] [Related]
12. Rapid characterization of carbapenem-resistant Enterobacterales by multiplex lateral flow assay and detection of ceftazidime-avibactam-aztreonam synergy.
Kalaivani R; Kali A; Surendran R; Sujaritha T; Ganesh Babu CP
Indian J Med Microbiol; 2024; 47():100530. PubMed ID: 38246242
[TBL] [Abstract][Full Text] [Related]
13. Aztreonam, Ceftazidime/Avibactam, and Colistin Combination for the Management of Carbapenemase-Producing
Shah PJ; Tran T; Emelogu F; Tariq F
J Pharm Pract; 2021 Aug; 34(4):653-657. PubMed ID: 31698984
[TBL] [Abstract][Full Text] [Related]
14.
Li D; Yu H; Huang X; Long S; Zhang J
Microbiol Spectr; 2023 Dec; 11(6):e0280623. PubMed ID: 37982631
[TBL] [Abstract][Full Text] [Related]
15. Impact of a Rapid Molecular Test for Klebsiella pneumoniae Carbapenemase and Ceftazidime-Avibactam Use on Outcomes After Bacteremia Caused by Carbapenem-Resistant Enterobacterales.
Satlin MJ; Chen L; Gomez-Simmonds A; Marino J; Weston G; Bhowmick T; Seo SK; Sperber SJ; Kim AC; Eilertson B; Derti S; Jenkins SG; Levi MH; Weinstein MP; Tang YW; Hong T; Juretschko S; Hoffman KL; Walsh TJ; Westblade LF; Uhlemann AC; Kreiswirth BN
Clin Infect Dis; 2022 Dec; 75(12):2066-2075. PubMed ID: 35522019
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for and clinical outcomes of ceftazidime-avibactam-resistant carbapenem-resistant Klebsiella pneumoniae nosocomial infections: a single-center retrospective study.
Liu X; Chu Y; Yue H; Huang X; Zhou G
Infection; 2022 Oct; 50(5):1147-1154. PubMed ID: 35182356
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of ceftazidime-avibactam in the treatment of carbapenem-resistant Klebsiella pneumoniae infections: Focus on solid organ transplantation recipients.
Hu J; Zha L; Yu YW; Su Q; Fang XL; Ji JR; Shen P; Chen YB; Zheng X; Xiao YH
Int J Antimicrob Agents; 2024 May; 63(5):107152. PubMed ID: 38513747
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection.
Shaw E; Rombauts A; Tubau F; Padullés A; Càmara J; Lozano T; Cobo-Sacristán S; Sabe N; Grau I; Rigo-Bonnin R; Dominguez MA; Carratalà J
J Antimicrob Chemother; 2018 Apr; 73(4):1104-1106. PubMed ID: 29272413
[No Abstract] [Full Text] [Related]
19. Efficacy and safety of ceftazidime-avibactam compared to other antimicrobials for the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae strains, a systematic review and meta-analysis.
Karampatakis T; Tsergouli K; Lowrie K
Microb Pathog; 2023 Jun; 179():106090. PubMed ID: 37004964
[TBL] [Abstract][Full Text] [Related]
20. Activity of ceftazidime-avibactam alone and in combination with polymyxin B against carbapenem-resistant Klebsiella pneumoniae in a tandem in vitro time-kill/in vivo Galleria mellonella survival model analysis.
Borjan J; Meyer KA; Shields RK; Wenzler E
Int J Antimicrob Agents; 2020 Jan; 55(1):105852. PubMed ID: 31770627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
